Shire once-daily guanfacine tablet gets FDA approval for ADHD treatment
The approval is based on the satisfactory results obtained from a 9-week, multicenter, double-blind, randomized, placebo-controlled study of INTUNIV in combination with a stimulant in children and adolescents
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.